GRI Bio, Inc.

GRI Nasdaq SEC CIK 1824293
Follow GRI Bio Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$1.5M +55.2% vs same quarter last year
EPS, diluted −$0.69
Operating cash flow −$1.5M +36.2% vs same quarter last year
Operating income −$1.5M +55.1% vs same quarter last year
Net income by quarter
−$1.9M
−$3M
−$2.9M
−$3.4M
−$2.7M
−$2M
−$1.6M
−$1.5M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
−$15M−$10M−$5M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$12M
FY24−$8.2M
FY23−$13M
FY22−$3.2M
FY21−$9.3M
FY20−$4.8M
FY19-
Free cash flowOperating cash flow minus capital expenditure
−$15M−$10M−$5M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$10.2M
FY24−$8.6M
FY23−$9M
FY22−$1.1M
FY21−$8.3M
FY20−$3.7M
FY19-